Mini Review
Published on 10 Nov 2022
A new strategy for osteoarthritis therapy: Inhibition of glycolysis
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1057229
- 7,715 views
- 21 citations
Type at least 3 characters
3,258 articles
Articles
Original Research
Published on 10 Nov 2022
2,4-Disubstituted pyridine derivatives are effective against intracellular and biofilm-forming tubercle bacilli
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1004632
- 2,146 views
- 3 citations
Original Research
Published on 10 Nov 2022
Integrating network pharmacology and experimental validation to clarify the anti-hyperuricemia mechanism of cortex phellodendri in mice
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.964593
- 5,389 views
- 10 citations
Original Research
Published on 09 Nov 2022
Prospective population pharmacokinetic study of tacrolimus in adult recipients early after liver transplantation: A comparison of Michaelis-Menten and theory-based pharmacokinetic models
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1031969
- 3,396 views
- 5 citations
Editorial
Published on 09 Nov 2022
Editorial: Women in experimental pharmacology and drug discovery: 2021
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1077670
- 2,329 views
Original Research
Published on 09 Nov 2022
Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.971905
- 1,784 views
- 3 citations
Original Research
Published on 09 Nov 2022
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.999685
- 3,683 views
- 4 citations
Review
Published on 09 Nov 2022
Receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1043975
- 2,957 views
- 16 citations
Review
Published on 08 Nov 2022
Cell penetrating peptide: A potent delivery system in vaccine development
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1072685
- 5,564 views
- 12 citations
Review
Published on 08 Nov 2022
The emerging roles and therapeutic potential of B cells in sepsis
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1034667
- 3,770 views
- 12 citations
Review
Published on 07 Nov 2022
Drug delivery systems for treatment of temporomandibular joint osteoarthritis
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1054703
- 3,725 views
- 1 citation
Correction
Published on 07 Nov 2022
Corrigendum: Editorial: The mechanisms of action of anti-SARS-CoV-2 drugs
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1065930
- 801 views
Original Research
Published on 04 Nov 2022
Anticholinesterase activity of Areca Catechu: In Vitro and in silico green synthesis approach in search for therapeutic agents against Alzheimer’s disease
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1044248
- 5,783 views
- 10 citations
Original Research
Published on 03 Nov 2022
Norcantharidin ameliorates estrogen deficient-mediated bone loss by attenuating the activation of extracellular signal-regulated kinase/ROS/NLRP3 inflammasome signaling
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1019478
- 1,456 views
- 3 citations
Original Research
Published on 02 Nov 2022
Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1037993
- 2,280 views
- 6 citations
Original Research
Published on 02 Nov 2022
Berbamine inhibits RANKL- and M-CSF-mediated osteoclastogenesis and alleviates ovariectomy-induced bone loss
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1032866
- 1,919 views
- 3 citations